CDT Equity Shares Scheduled to Reverse Split on Monday, July 20th (NASDAQ:CDT)

Shares of CDT Equity Inc. (NASDAQ:CDT – Free Report) are scheduled to reverse split on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 19th.

CDT Equity Price Performance

Shares of CDT traded up $0.00 during mid-day trading on Thursday, hitting $0.35. The stock had a trading volume of 888,099 shares, compared to its average volume of 3,301,149. CDT Equity has a 52 week low of $0.30 and a 52 week high of $461.54. The business has a fifty day moving average price of $0.92 and a 200-day moving average price of $12.33. The firm has a market cap of $1.72 million, a P/E ratio of -0.00 and a beta of 1.49.

Get CDT Equity alerts:

CDT Equity (NASDAQ:CDT – Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported ($5.56) earnings per share for the quarter.

Analyst Ratings Changes

A number of analysts recently commented on CDT shares. Wall Street Zen cut shares of CDT Equity to a “strong sell” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Read Our Latest Research Report on CDT Equity

About CDT Equity

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Further Reading

• Five stocks we like better than CDT Equity
• Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Revving Up Returns: Big Banks Race Through the Rate Plateau
• Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
• Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test

Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.